A Pilot Evaluation of Expedited Partner Treatment and Partner Human Immunodeficiency Virus Self-Testing Among Adolescent Girls and Young Women Diagnosed With Chlamydia trachomatis and Neisseria gonorrhoeae in Kisumu, Kenya.
A Pilot Evaluation of Expedited Partner Treatment and Partner Human Immunodeficiency Virus Self-Testing Among Adolescent Girls and Young Women Diagnosed With Chlamydia trachomatis and Neisseria gonorrhoeae in Kisumu, Kenya.
复制标题
DOI：
10.1097/olq.0000000000001430
复制
发表时间：
2021-10-01
影响因子：
3.1
通讯作者：
Baeten JM
中科院分区：
文献类型：
--
作者：
Omollo V;Bukusi EA;Kidoguchi L;Mogaka F;Odoyo JB;Celum C;Morton J;Johnson R;Baeten JM
在接受暴露前预防的被诊断为沙眼衣原体或淋病奈瑟菌的年轻女性中进行的一项试点研究发现，快速伴侣治疗和伴侣人类免疫病毒自我检测的可接受性和接受率很高。快速伴侣治疗（EPT）对于预防性传播感染复发是有效的，但对亲密伴侣暴力和错过人类免疫病毒（HIV）检测机会的担忧限制了其在非洲环境中的使用。我们在肯尼亚基苏穆的一个实施项目中，对接受艾滋病毒暴露前预防的少女和年轻妇女（AGYW）进行了一项EPT的试点前瞻性评价。那些病原学诊断为沙眼衣原体和淋病奈瑟菌的人得到了治疗，并可以选择向他们目前的性伴侣提供性传播感染药物和艾滋病毒自我检测试剂盒。在招募时，我们评估了他们下降的原因。在他们向伴侣提供药物和试剂盒三个月后，我们评估了他们未能向伴侣提供药物和试剂盒的原因，并报告了伴侣的反应。2018年9月至2020年3月，63名AGYW入组。大多数人（59/63 [94%]）接受EPT，63名伴侣中有50名（79%）接受艾滋病毒自我检测（HIVST）。四分之三（46/59）接受EPT的人返回进行评估访问，46人中有41人（89%）成功地向54名伴侣提供药物，其中49人（91%）使用了药物。70%（35/50）接受伴侣HIVST试剂盒的人返回进行评估，80%（28/35）报告向40名伴侣提供了试剂盒，据报告，在拒绝接受EPT和伴侣艾滋病毒/艾滋病防治的妇女中，接受EPT和伴侣艾滋病毒/艾滋病防治的障碍包括预期担心其伴侣可能变得愤怒或暴力以及失去关系。EPT和伴侣HIVST都是可以接受的，尽管肯尼亚AGYW与沙眼衣原体/淋病奈瑟菌及其伴侣的病原学诊断存在障碍。
A pilot study among young women receiving preexposure prophylaxis who were diagnosed with Chlamydia trachomatis or Neisseria gonorrhoeae found high acceptability and uptake of expedited partner treatment and partner human immunology virus self-testing. Expedited partner treatment (EPT) is effective for preventing sexually transmitted infection recurrence, but concerns about intimate partner violence and missed opportunities for human immunology virus (HIV) testing have limited its use in African settings. We conducted a pilot prospective evaluation of EPT among adolescent girls and young women (AGYW) accessing HIV preexposure prophylaxis in an implementation project in Kisumu, Kenya. Those with etiologic diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae were treated and given the option of delivering sexually transmitted infection medication and HIV self-test kits to their current sexual partner(s). At enrollment, we assessed their reasons for declining. Three months after they delivered medication and kits to the partner(s), we assessed their reasons for failing to deliver medication and kits to their partner and reported partner's reactions. Between September 2018 and March 2020, 63 AGYW were enrolled. The majority (59/63 [94%]) accepted EPT, and 50 (79%) of 63 partner HIV self-testing (HIVST). Three quarters (46/59) of those accepting EPT returned for the assessment visit with 41 (89%) of 46 successfully delivering medication to 54 partners, of whom 49 (91%) used it. Seventy percent (35/50) who took partner HIVST kits returned for the assessment, with 80% (28/35) reporting providing kits to 40 partners, of whom 38 (95%) used it. Reported barriers to EPT and partner HIVST uptake among women who declined included anticipated fear that their partner could become angry or violent and loss of relationship. Both EPT and partner HIVST were acceptable despite noted barriers among Kenyan AGYW with etiologic diagnosis of Chlamydia trachomatis/Neisseria gonorrhoeae and their partners.